Vaccine maker Novavax said Monday its COVID-19 shot was highly effective against the disease and also protected against variants in a large study in the U.S. and Mexico, potentially offering the world another weapon against the virus.<\/b>
\nVaccine maker Novavax said Monday its COVID-19 shot was highly effective against the disease and also protected against variants in a large study in the U.S. and Mexico, potentially offering the world another weapon against the virus. The two-shot vaccine was about 90% effective overall, and preliminary data showed it was safe, the American company said. That would put the vaccine about on par with Pfizer\u2019s and Moderna\u2019s. While demand for COVID-19 shots in the U.S. has dropped off dramatically, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting supplies in poor parts of the world. That help is still months away, however. The company, which has been plagued by raw-material shortages that have hampered production, said it plans to seek authorization for the shots in the U.S., Europe and elsewhere by the end of September and will be able to produce up to 100 million doses a month by then. \u201cMany of our first doses will go to\u2026 low- and middle-income countries, and that was the goal to begin with,\u201d Novavax CEO Stanley Erck said. While more than half of the U.S. population has had at least one vaccine dose, less than 1% of people in the developing world have had one shot, according to a data collection effort run in part by the University of Oxford. The Novavax shot stands to become the fifth Western-developed COVID-19 vaccine to win clearance. The Pfizer, Moderna and Johnson & Johnson vaccines are already authorized for use in the U.S. and Europe. Europe also uses AstraZeneca\u2019s formula. Novavax\u2019s study involved nearly 30,000 people ages 18 and up. Two-thirds received two doses of the vaccine, three weeks apart, and the rest got dummy shots. Nearly half the volunteers were Black, Hispanic, Asian American or Native American, and 6% of participants were in Mexico. Altogether,37% had health problems that made them high risk, and 13% were 65 or older. There were 77 cases of COVID-19 \u2014 14 in the group that got the vaccine, the rest in volunteers who received the dummy shots. None in the vaccine group had moderate or severe disease, compared with 14 in the placebo group. One person in that group died. The vaccine was similarly effective against several variants, including the one first detected in Britain that is now dominant in the U.S., and in high-risk populations, including the elderly and people with other health problems. \u201cThese consistent results provide much confidence in the use of this vaccine for the global population,\u201d said Dr. Paul Heath, director of the Vaccine Institute at the University of London and St. George\u2019s Hospital. Side effects were mostly mild \u2014 tenderness and pain at the injection site. There were no reports of unusual blood clots or heart problems, Erck said.<\/p>\n